Pasar al contenido principal

Resultados de investigación

Rights
Projectcode
Resultados totales (Incluyendo duplicados): 24008
Encontrada(s) 2401 página(s)
Recercat. Dipósit de la Recerca de Catalunya
oai:recercat.cat:2117/344175
Publicación

Assessment of automatic decision-support systems for detecting active t2 lesions in multiple sclerosis patients

  • Corral, Juan Francisco
  • Alonso, Juli
  • Auger, Cristina
  • Valverde Valverde, Sergi
  • Vidal Jordana, Ángela
  • Oliver, Arnau
  • Barros, Andrea
  • Ng Wong, Karelis
  • Tintoré, Mar
  • Aymerich Martínez, Francisco Javier
  • Montalban, Xavier
  • Lladó, Xavier
  • Rovira Cañellas, Alex
Postprint (author's final draft)
Recercat. Dipósit de la Recerca de Catalunya
oai:recercat.cat:2117/357256
Publicación

Autofluorescence of stingray skeletal cartilage: hyperspectral imaging as a tool for histological characterization

  • de Juan, Ana
  • Dean, Mason
  • Gualda Manzano, Emilio José
  • Marsal, Maria
  • Loza Álvarez, Pablo
  • Chaumel, Júlia
  • Gómez Sánchez, Adrián
  • Blumer, Michael
Tessellated cartilage is a distinctive composite tissue forming the bulk of the skeleton of cartilaginous fishes (e.g. sharks and rays), built from unmineralized cartilage covered at the surface by a thin layer of mineralized tiles called tesserae. The finescale structure and composition of elasmobranch tessellated cartilage has largely been investigated with electron microscopy, micro-computed tomography and histology, but many aspects of tissue structure and composition remain uncharacterized. In our study, we demonstrate that the tessellated cartilage of a stingray exhibits a strong and diverse autofluorescence, a native property of the tissue which can be harnessed as an effective label-free imaging technique. The autofluorescence signal was excited using a broad range of wavelengths in confocal and light sheet microscopy, comparing several sample preparations (fresh; demineralized and paraffin-embedded; non-demineralized and plastic-embedded) and imaging the tissue at different scales. Autofluorescence varied with sample preparation with the signal in both plastic- and paraffin-embedded samples strong enough to allow visualization of finescale (=¿1 µm) cellular and matrix structures, such as cell nuclei and current and former mineralization fronts, identifiable by globular mineralized tissue. A defined pericellular matrix (PCM) surrounding chondrocytes was also discernible, described here for the first time in elasmobranchs. The presence of a PCM suggests similarities with mammalian cartilage regarding how chondrocytes interact with their environment, the PCM in mammals acting as a transducer for biomechanical and biochemical signals. A posterior analysis of hyperspectral images by an MCR-ALS unmixing algorithm allowed identification of several distinct fluorescence signatures associated to specific regions in the tissue. Some fluorescence signatures identified could be correlated with collagen type II, the most abundant structural molecule of cartilage. Other fluorescence signatures, however, remained unidentified, spotlighting tissue regions that deserve deeper characterization and suggesting the presence of molecules still unidentified in elasmobranch skeletal cartilage. Our results show that autofluorescence can be a powerful exploratory imaging tool for characterizing less-studied skeletal tissues, such as tessellated cartilage. The images obtained are largely comparable with more commonly used techniques, but without the need for complicated sample preparations or external staining reagents standard in histology and electron microscopy (TEM, SEM)., Postprint (published version)
idUS. Depósito de Investigación de la Universidad de Sevilla
oai:idus.us.es:11441/167278
Datos de investigación Set de datos (Dataset)

Neuromorphic Audio for Predictive Maintenance in Peristaltic Pumps [Dataset]

Audio neuromórfico para mantenimiento predictivo en bombas peristálticas [Dataset]
  • Montes-Sánchez, Juan Manuel
  • Domínguez Morales, Juan Pedro
  • Vicente Díaz, Saturnino
  • Jiménez Fernández, Ángel Francisco
This dataset contains processed audio samples coming from a hydraulic block from a biomedical equipment. The block mounts 3 Thomas SR10/30 DC standard perisltaltic pumps, which were filled with distilled water. Only one pump was running at the same time during these recordings. There are two different predictive maintenance scenarios. In the first one, the cassettes of the pumps were changed before each recording. We used cassettes with 2 different levels of degradation: NEW (unused) and OLD (lifetime already expired). We defined 3 different classes: Class 1 is STOP (no pump running), class 2 is NEW (one pump running with a new cassette), and class 3 is OLD (one pump running with an old cassette). In the second scenario, air bubbles were introduced into the tube. This second scenario also has 3 classes: Class 1 is STOP (no pump running), class 2 is NORMAL (no air bubbles), and class 3 is BUBBLE (air bubbles present). A single microphone was used for all recordings. The .wav audio files were processed using a 64 channel Neuromorphic Auditory Sensor (NAS) into .aedat files, which are the present in this dataset. This neuromorphic audio data were also converted into cochleogram images using the software pyNAVIS, and they are also present in this format (.png files)., There is one folder for each of the two scenarios (aging and bubble). Inside those folders there are 3 subfolders, one for each data type (AEDAT, PNG and WAV). For WAV and AEDAT, each file is a unique sample tagged with one class (1, 2 or 3). At the end of each filename this class is also included. For example, 0008_03.wav is the sample number 8, which corresponds to class 3 tagged data. PNG cochleogram images represent 500ms audio time each and are named after their source AEDAT file followed by their starting time mark in microseconds.
idUS. Depósito de Investigación de la Universidad de Sevilla
oai:idus.us.es:11441/162880
Datos de investigación Set de datos (Dataset)

Peristaltic pump aging detection dataset

Dataset para detección de envejecimiento de bombas peristálticas
  • Montes-Sánchez, Juan Manuel
  • Uwate, Yoko
  • Nishio, Yoshifumi
  • Vicente Díaz, Saturnino
  • Jiménez Fernández, Ángel Francisco
This dataset contains samples coming from a hydraulic block from a biomedical equipment. The block mounts 3 Thomas SR10/30 DC standard perisltaltic pumps, which were filled with distilled water. Only one pump was running at the same time during these recordings, always at maximum constant speed. The cassettes of the pumps were changed before each recording. We used cassettes with 2 different levels of degradation: NEW (unused) and OLD (lifetime already expired). We defined 3 different classes: Class 1 is STOP (no pump running), class 2 is NEW (one pump running with a new cassette), and class 3 is OLD (one pump running with an old cassette). The classified samples were recorded using several sensors: 3 accelerometers, 1 gyroscope, 1 magnetometer and 1 microphone. All data were recorded at the same time at the maximum available frequency using the device "ST SensorTile.box". The raw data has already been processed into sepparate different .csv files (.wav files for audio) using python code., Each sensor has its own folder. The sensor folder name starts with ACC for accelerometer data, GYRO for gyroscope data, MAG for magnetometer data or MIC for microphone data. After that, the name of the sensor. At the end, sampling frequency in Hz. For example: ACC_LISDW12_1600Hz folder contains data for the accelerometer named LISDW12 at a sampling rate of 1600Hz. Each sensor folder contains 17 .csv files except for the microphone folder, which contains 17 .wav files. Each file is a unique sample tagged with one class (1, 2 or 3). At the end of each filename this class is also included. For example, 0008_03.csv is the sample number 8, which corresponds to class 3 tagged data.
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/22179
Publicación Otros (Other)

A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial.

  • Climent, Miguel-A
  • Font, Albert
  • Duran, Ignacio
  • Puente, Javier
  • Mendez-Vidal, Maria-Jose
  • Saez, Maria-Isabel
  • Santander-Lobera, Carmen
  • Arranz-Arija, Jose-Angel
  • Gonzalez-del-Alba, Aranzazu
  • Sanchez-Hernandez, Alfredo
  • Juan-Fita, Maria-Jose
  • Esteban, Emilio
  • Alonso-Gordoa, Teresa
  • Mellado-Gonzalez, Begoña
  • Maroto, Pablo
  • Lazaro-Quintela, Martin
  • Cassinello-Espinosa, Javier
  • Perez-Valderrama, Begoña
  • Garcias, Carmen
  • Castellano, Daniel
We aimed to compare the efficacy and safety of maintaining or withdrawing abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-resistant prostate cancer who had experienced cancer progression to this treatment and were beginning a docetaxel-based therapy. Phase II, randomised, open-label study conducted in patients with metastatic castration-resistant prostate cancer who were asymptomatic or mildly symptomatic. After open-label treatment with AAP, patients who had experienced cancer progression to AAP were randomised to 75 mg/m2 of docetaxel plus AAP or to receive 75 mg/m2 of docetaxel plus 10 mg of prednisone orally daily. The primary outcome was the radiographic progression-free survival rate at 12 months as evaluated by the investigators in all randomised patients. A total of 148 patients were included in open-label treatment with AAP, and of them, 94 patients were randomised to receive either docetaxel plus AAP (intervention group; n = 47) or docetaxel plus prednisone (control group; n = 47). The 12-month radiographic progression-free survival rates did not differ between the intervention group (34.9%; 95% CI 20.7-49.2) and the control group (33.9%; 95% CI 19.5-48.3). There were no significant differences in the time to radiographic progression and the overall survival between the intervention and control groups. Grade 3-5 neutropenia with the combination of docetaxel plus prednisone and AA was more frequent than with docetaxel plus prednisone (59.6% versus 27.7%). Our results indicate that the therapeutic strategy of maintaining AAP added to docetaxel in chemotherapy-naïve patients who have experienced cancer progression to AAP treatment should not be further evaluated and should be avoided in clinical practice., Si
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/16589
Publicación Otros (Other)

Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma.

  • Martin-Broto, Javier
  • Lopez-Pousa, Antonio
  • Brohl, Andrew-S
  • Van-Tine, Brian-A
  • Powers, Benjamin
  • Stacchiotti, Silvia
  • Blay, Jean-Yves
  • Hu, James-S
  • Oakley, Gerard-J
  • Wang, Hong
  • Szpurka, Anna-M
  • Levy, Donna-E
  • Mo, Gary
  • Ceccarelli, Matteo
  • Jones, Robin-L
This phase Ib study enumerated whole blood circulating tumor cells (CTC) and evaluated biomarkers in patients with potentially resectable soft-tissue sarcoma (STS) treated with olaratumab monotherapy (20 mg/kg) for one cycle followed by up to six cycles of olaratumab (20 mg/kg, cycles 1-2; 15 mg/kg, cycles 3-7) plus doxorubicin (75 mg/m2 on day 1). CTCs, platelet-derived growth factor receptors (PDGFR), and PDGF ligand expression in tumor tissue pre- and post-olaratumab monotherapy were evaluated. Antitumor activity, safety, pharmacokinetics, and PET/biomarker association with clinical outcome were assessed. Of 51 treated patients, 35, 43, and 37 were evaluable for CTC enumeration, PDGFRs, and PDGF ligand expression, respectively. An increase in CTCs at cycle 1 day 8 was observed, followed by a significant reduction by cycle 3 day 1 or 30-day follow-up. Decrease in CTC counts after olaratumab monotherapy was higher in patients with disease control than without disease control (57.9% vs. 31.2%). Baseline IHC expression was positive in most patients for PDGFRα [n = 31 (72.1%)] and PDGFRβ [n = 36 (83.7%)]. Similar rates were observed post-olaratumab monotherapy [PDGFRα, n = 30 (69.8%); PDGFRβ, n = 33 (76.7%)]. Eleven patients (29.7%) showed a 30% reduction by RT-PCR in PDGFRα at cycle 2. PDGFR expression and PET response showed no correlation with clinical outcome. Safety and pharmacokinetic profiles were consistent with previous reports. This study, the first to use a validated method for CTC detection, confirms that CTC enumeration in STS is feasible. However, no correlation was observed between PDGFRα expression and clinical outcome., Si
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/14823
Publicación Otros (Other)

Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin and Suboptimal HbA1c in Andalusia (Spain): PLATEDIAN Study.

  • Ruiz de Adana, Maria S
  • Alhambra-Exposito, Maria Rosa
  • Muñoz-Garach, Araceli
  • Gonzalez-Molero, Inmaculada
  • Colomo, Natalia
  • Torres-Barea, Isabel
  • Aguilar-Diosdado, Manuel
  • Carral, Florentino
  • Serrano, Manuel
  • Martinez-Brocca, Maria A
  • Duran, Ana
  • Palomares, Rafael
Objective: To assess the impact of a telemedicine visit using the platform Diabetic compared with a face-to-face visit on clinical outcomes, patients' health-related quality of life (HRQoL), and physicians' satisfaction in patients with type 1 diabetes. Research design and methods: PLATEDIAN (Telemedicine on Metabolic Control in Type 1 Diabetes Mellitus Andalusian Patients) (NCT03332472) was a multicenter, randomized, 6-month follow-up, open-label, parallel-group controlled study performed in patients with type 1 diabetes with suboptimal metabolic control (HbA1c <8% [<64 mmol/mol]), treated with multiple daily injections. A total of 388 patients were assessed for eligibility; 379 of them were randomized 1:1 to three face-to-face visits (control cohort [CC]) (n = 167) or the replacement of an intermediate face-to-face visit by a telemedicine visit using Diabetic (intervention cohort [IC]) (n = 163). The primary efficacy end point was the mean change of HbA1c levels from baseline to month 6. Other efficacy and safety end points were mean blood glucose, glucose variability, episodes of hypoglycemia and hyperglycemia, patient-reported outcomes, and physicians' satisfaction. Results: At month 6, the mean change in HbA1c levels was -0.04 ± 0.5% (-0.5 ± 5.8 mmol/mol) in the CC and 0.01 ± 0.6% (0.1 ± 6.0 mmol/mol) in the IC (P = 0.4941). The number of patients who achieved HbA1c <7% (<53 mmol/mol) was 73 and 78 in the CC and IC, respectively. Significant differences were not found regarding safety end points at 6 months. Changes in HRQoL between the first visit and final visit did not differ between cohorts, and, regarding fear of hypoglycemia (FH-15 score ≥28), statistically significant differences observed at baseline remained unchanged at 6 months (P < 0.05). Conclusions: The use of telemedicine in patients with type 1 diabetes with HbA1c <8% (<64 mmol/mol) provides similar efficacy and safety outcomes as face-to-face visits., Si
Recercat. Dipósit de la Recerca de Catalunya
oai:recercat.cat:2117/103444
Datos de investigación Set de datos (Dataset)

Geostandards of the Valentí Masachs Geology Museum

Geostandards du Musée de Géologie Valentí Masachs
  • Parcerisa Duocastella, David
  • Fàbrega Alsina, Carles
  • Gurenko, Andrey
  • Franke, Christine
Anàlisis geoquímiques i fotos de visu i microscòpia de les mostres que integren la col·lecció de geostandards del Museu de Geologia Valentí Masachs (UPC Manresa). Análisis geoquímicas y fotos de visu y microscopio de las muestras que integran la colección de geostandares del Museo de Geología Valentí Masachs (UPC Manresa). Geochemical analyses and hand and microscopy pictures of the samples belonging to the geostandards collection of the Valenti Masachs Geology Museum (UPC Manresa). Analyses géochimiques et photographies au microscope et visu des échantillons qui forment la collection de geostandards du Musée de Géologie Valentí Masachs (UPC Manresa)., 1
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/29939
Publicación Otros (Other)

Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.

  • Necchi, Andrea
  • Ramlau, Rodryg
  • Falcon-Gonzalez, Alejandro
  • Chaudhry, Arvind
  • Todenhöfer, Tilman
  • Tahbaz, Rana
  • Fontana, Elisa
  • Giannatempo, Patrizia
  • Deville, Jean-Laurent
  • Pouessel, Damien
  • Yoon, Shinkyo
  • Powles, Thomas
  • Bernat, Mathieu
  • Häckl, Manuel
  • Marszewska, Michalina
  • McKernan, Phil
  • Saulay, Mikael
  • Scaleia, Federica
  • Engelhardt, Marc
  • Loriot, Yohann
  • Siefker-Radtke, Arlene
  • Santis, Maria-de
This Phase 1b/2 study assessed the efficacy in terms of objective response rate (ORR) of the FGFR1/2/3 kinase inhibitor derazantinib as monotherapy or in combination with atezolizumab in patients with metastatic urothelial cancer (mUC) and FGFR1-3 genetic aberrations (FGFR1-3GA). This multicenter, open-label study comprised 5 substudies. In Substudies 1 and 5, patients with mUC with FGFR1-3GA received derazantinib monotherapy (300 mg QD in Substudy 1, 200 mg BID in Substudy 5). In Substudy 2, patients with any solid tumor received atezolizumab 1200 mg every 3 weeks plus derazantinib 200 or 300 mg QD. In Substudy 3, patients with mUC harboring FGFR1-3GA received derazantinib 200 mg BID plus atezolizumab 1200 mg every 3 weeks. In Substudy 4, patients with FGFR inhibitor-resistant mUC harboring FGFR1-3GA received derazantinib 300 mg QD monotherapy or derazantinib 300 mg QD plus atezolizumab 1200 mg every 3 weeks. The ORR for Substudies 1 and 5 combined was 4/49 (8.2%, 95% confidence interval = 2.3% to 19.6%), which was based on 4 partial responses. The ORR in Substudy 4 was 1/7 (14.3%, 95% confidence interval = 0.4% to 57.9%; 1 partial response for derazantinib 300 mg monotherapy, zero for derazantinib 300 mg plus atezolizumab 1200 mg). In Substudy 2, derazantinib 300 mg plus atezolizumab 1200 mg was identified as a recommended dose for Phase 2. Only 2 patients entered Substudy 3. Derazantinib as monotherapy or in combination with atezolizumab was well-tolerated but did not show sufficient efficacy to warrant further development in mUC. Clinicaltrials.gov NCT04045613, EudraCT 2019-000359-15.
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/17369
Publicación Otros (Other)

Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.

  • Heuser, Michael
  • Smith, B-Douglas
  • Fiedler, Walter
  • Sekeres, Mikkael-A
  • Montesinos, Pau
  • Leber, Brian
  • Merchant, Akil
  • Papayannidis, Cristina
  • Perez-Simon, Jose-A
  • Hoang, Caroline-J
  • O'Brien, Thomas
  • Ma, Weidong-Wendy
  • Zeremski, Mirjana
  • O'Connell, Ashleigh
  • Chan, Geoffrey
  • Cortes, Jorge-E
This analysis from the phase II BRIGHT AML 1003 trial reports the long-term efficacy and safety of glasdegib + low-dose cytarabine (LDAC) in patients with acute myeloid leukemia ineligible for intensive chemotherapy. The multicenter, open-label study randomized (2:1) patients to receive glasdegib + LDAC (de novo, n = 38; secondary acute myeloid leukemia, n = 40) or LDAC alone (de novo, n = 18; secondary acute myeloid leukemia, n = 20). At the time of analysis, 90% of patients had died, with the longest follow-up since randomization 36 months. The combination of glasdegib and LDAC conferred superior overall survival (OS) versus LDAC alone; hazard ratio (HR) 0.495; (95% confidence interval [CI] 0.325-0.752); p = 0.0004; median OS was 8.3 versus 4.3 months. Improvement in OS was consistent across cytogenetic risk groups. In a post-hoc subgroup analysis, a survival trend with glasdegib + LDAC was observed in patients with de novo acute myeloid leukemia (HR 0.720; 95% CI 0.395-1.312; p = 0.14; median OS 6.6 vs 4.3 months) and secondary acute myeloid leukemia (HR 0.287; 95% CI 0.151-0.548; p < 0.0001; median OS 9.1 vs 4.1 months). The incidence of adverse events in the glasdegib + LDAC arm decreased after 90 days' therapy: 83.7% versus 98.7% during the first 90 days. Glasdegib + LDAC versus LDAC alone continued to demonstrate superior OS in patients with acute myeloid leukemia; the clinical benefit with glasdegib + LDAC was particularly prominent in patients with secondary acute myeloid leukemia., Si
Buscador avanzado